Refine by
Hepatitis B Articles & Analysis
56 news found
Creative Diagnostics, a leading manufacturer and supplier of antibodies, antigens and assay kits, has announced the expansion of its Hepatitis B research portfolio with a comprehensive range of sensitive and specific Hepatitis B Virus Surface Antigen L-proteins. ...
Stem cell therapy is a groundbreaking field in the pharmaceutical industry, offering powerful tools for treating severe diseases such as cancer. The genetic manipulations involved in this process, however, necessitate stringent regulations to ensure sterility and safety. In 2017, the Food and Drug Administration (FDA) took significant steps towards regulating stem cell therapy, marking a pivotal ...
Antengene also highlighted data from the 45 milligram (mg) per day monotherapy dosing cohort of the open-label Phase II TORCH Trial in subjects with Hepatitis B positive (HBV+) unresectable HCC who have received at least one prior line of systemic therapy (NCT03591965). ...
” “We are pleased to be able to maintain and increase our support of VBI’s commercialization and pipeline development efforts, and we look forward to continuing to work with the VBI team in their mission to address significant unmet needs in infectious disease and oncology,” said Anup Arora, Founding Managing Director and Chief Investment Officer of K2HV. About ...
(Nasdaq: VBIV) (VBI) today announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine (recombinant, adsorbed)], the only 3-antigen hepatitis B vaccine approved in Europe. ...
Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of VBI’s 3-Antigen Hepatitis B Vaccine (HBV), PreHevbrio™ [Hepatitis B Vaccine (Recombinant)]. ...
Additional objectives were to determine the proportion of participants who retained anti-HBs titers ≥ 10 mIU/mL and anti-HBs titers ≥ 100 mIU/mL 2.5 years after the completion of vaccination. About Hepatitis B Hepatitis B is one of the world’s most significant infectious disease threats with more than 290 million ...
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 22, 2022 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ...
VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). ...
” Key results from the ASCO poster presentation: Data were collected as of May 9, 2022 VBI-1901 + GM-CSF Study Arm – High Dose Part A + Part B (n=16) Two (2) partial tumor responses and five (5) stable disease seen across Part A and Part B 18-month overall survival (OS) of 25% (n=4/16) Median OS (mOS) reached at 12.9 months, comparing ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
It can be expected that hepatitis D will also be prevented by immunisation with PreHevbri as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection. ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
Oral Presentation Details Abstract Number: 1416 Title: Long term persistence of Anti-HBs antibodies after vaccination with a 3-antigen HBV vaccine compared to a single-antigen HBV vaccine Session: Viral hepatitis B/D: Clinical aspects except therapy Date: Sunday, June 26, 2022 Time: 10:00-11:30 AM BST Presenter: Timo Vesikari, M.D., Ph.D., Professor ...
The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, ...
In addition, Altimmune is developing HepTcell™, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis ...
The Company has two commercial products, HEPLISAV-B® vaccine [Hepatitis B Vaccine (Recombinant), Adjuvanted], which is approved in the U.S. and the European Union for the prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older, and CpG 1018 adjuvant, ...
Wainwright Global Investment Conference Tuesday, May 24, 2022 7:00 am Eastern Time The session will be webcast and can be accessed by visiting the Events section of the Altimmune website. B. Riley Securities Institutional Investor Conference Thursday, May 26, 2022 1:00 pm Pacific Time The session will be an in person fireside chat. ...